Vicore Pharma Holding Stock Last Dividend Paid
VICO Stock | SEK 7.84 0.36 4.39% |
Vicore Pharma Holding fundamentals help investors to digest information that contributes to Vicore Pharma's financial success or failures. It also enables traders to predict the movement of Vicore Stock. The fundamental analysis module provides a way to measure Vicore Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vicore Pharma stock.
Vicore |
Vicore Pharma Holding Company Last Dividend Paid Analysis
Vicore Pharma's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition |
Based on the recorded statements, Vicore Pharma Holding has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
All Next | Launch Module |
Vicore Fundamentals
Return On Equity | -0.99 | |||
Return On Asset | -0.49 | |||
Current Valuation | 1.22 B | |||
Shares Outstanding | 81.85 M | |||
Shares Owned By Insiders | 16.14 % | |||
Shares Owned By Institutions | 51.89 % | |||
Price To Earning | 163.82 X | |||
Price To Book | 8.67 X | |||
EBITDA | (293.13 M) | |||
Net Income | (296.48 M) | |||
Cash And Equivalents | 215.97 M | |||
Cash Per Share | 5.10 X | |||
Total Debt | 320 K | |||
Current Ratio | 19.83 X | |||
Book Value Per Share | 2.24 X | |||
Cash Flow From Operations | (265.17 M) | |||
Earnings Per Share | (4.76) X | |||
Target Price | 69.6 | |||
Number Of Employees | 23 | |||
Beta | 0.59 | |||
Market Capitalization | 1.26 B | |||
Total Asset | 451.17 M | |||
Net Asset | 451.17 M |
About Vicore Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vicore Pharma Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vicore Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vicore Pharma Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vicore Stock Analysis
When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.